FindTrial
Sign In

Homoeopathic treatment of ovarian cysts

Effectiveness of individualized homoeopathic medicines versus Oophorinum in polycystic ovarian syndrome (PCOS): An open-label randomized pragmatic clinical trial

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012573
Enrollment
64
Registered
2018-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Oophorinum in centesimal or 50 millesimal potencies: In centesimal scale, each dose consist of a single drop of Fagopyrum esculentum (preserved in 90% v/v ethanol) in 5 ml of distilled
dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globule of poppy seed size (no. 10) will be dissolved in 90 ml disti
16 doses to be marked on the vial
each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th
dosage and repetition depending upon the individual requirement of the cases. In 50 millesimal scale, a single medicated cane sugar globule of poppy seed size (no. 10) will be dissolved in 90 ml disti
each dose of 5 ml to be taken after 10 uniformly forceful downward strokes to the vial in 45 ml normal water in a clean cup, to stir well, to take 5 ml of this liquid orally, and to discard rest of th

Sponsors

National Institute of Homoeopathy Ministry of AYUSH Govt of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed PCOS as per Rotterdam diagnostic criteria 2. Age 18-45 years 3. Symptomatic for at least last 3 months 4. Patients taking oral contraceptive pills (OCPs) will be advised to stop pills till it exhaust for the ongoing cycle, followed by re-assessment of symptoms in the next cycle enrolment 5. Patients under hormonal replacement therapy (HRT) to be included after a washout period of 3 months 6. Ability to read Bengali 8. Patients giving written consent to participate

Exclusion criteria

Exclusion criteria: 1. Unevaluated gynaecological abnormalities; e.g. unexplained vaginal bleeding, cervical dysplasia, pelvic inflammatory diseases (PID) within one month, patients with suspicious adenomyosis, gross developmental defect or congenital abnormalities of the uterus etc. 2. Genito-urinary tract malignancy 3. Patients desiring immediate surgical management for PCOS 4. Patients insisting to use OCPs 5. Patients with psychiatric diseases 6. Pregnancy and lactation 7. Cases suffering from uncontrolled systemic illness or life-threatening infections or any vital organ failure 8. Cases already undergoing homoeopathic treatment for any chronic disease 9. Substance abuse and/or dependence 10. Self-reported immune-compromised state

Design outcomes

Primary

MeasureTime frame
Pelvic/transvaginal ultrasound and blood LH:FSH levelTimepoint: Baseline and after 6 months—

Secondary

MeasureTime frame
EQ-5D-5L questionnaire; validated Bengali versionTimepoint: Baseline, after 3 and 6 months;Modified PCOS questionnaire (MPCOSQ); translated Bengali versionTimepoint: Baseline, after 3 and 6 months—

Countries

India

Contacts

Public ContactAbhijit Chattopadhyay

National Institute of Homoeopathy, Ministry of AYUSH, Govt. of India

drac.nih@gmail.com7003547446

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026